https://orcid.org/0000-0002-7098-3095
References
- Borthakur G, Popplewell L, Boyiadzis M, et al. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016;122(12):1871–1879.
- Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019;567(7749):521–524.
- Steven H, Swerdlow EC, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. In Bosman ESJ FT, Lakhani SR, Ohgaki H, editors. World Health Organization classification of tumours. Revised 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2017. p. 89.
- Hasegawa D, Manabe A, Kubota T, et al. Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia. Br J Haematol. 2005;128(6):805–812.
- Johan MF, Bowen DT, Frew ME, et al. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 2005;129(1):60–65.
- Liu YL, Castleberry RP, Emanuel PD. PTEN deficiency is a common defect in juvenile myelomonocytic leukemia. Leuk Res. 2009;33(5):671–677.
- Olk-Batz C, Poetsch AR, Nollke P, et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood. 2011;117(18):4871–4880.
- Flotho C, Sommer S, Lubbert M. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia. Semin Cancer Biol. 2018;51:68–79.
- Kim DY, Lee JH, Park YH, et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant. 2012;47(3):374–379.
- Oshrine B. Primary graft failure but treatment success: a case of reversion to heterozygosity after allogeneic hematopoietic cell transplantation with autologous hematopoietic recovery in a child with CBL-related juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol. 2021;43(3):e426–e428.